5734-66-7

Usage

Uses

Used in Pharmaceutical Industry:
4(1H)-Pyrimidinone, 2-amino-6-ethyl(9CI) is used as a pharmaceutical intermediate for the development of new drugs. Its unique chemical structure allows it to be a versatile component in the synthesis of various therapeutic agents, targeting a wide range of medical conditions.
Used in Research and Development:
In the field of research and development, 4(1H)-Pyrimidinone, 2-amino-6-ethyl(9CI) serves as a valuable compound for studying the structure-activity relationships of pyrimidine-based drugs. This helps researchers to design and optimize more effective and safer medications for various diseases.
Used in Agrochemical Industry:
4(1H)-Pyrimidinone, 2-amino-6-ethyl(9CI) can also be utilized as an intermediate in the agrochemical industry for the synthesis of pesticides and other crop protection agents. Its incorporation into these products can enhance their efficacy and selectivity, leading to improved agricultural yields and reduced environmental impact.

InChI:InChI=1/C6H9N3O/c1-2-4-3-5(10)9-6(7)8-4/h3H,2H2,1H3,(H3,7,8,9,10)

Upstream product

• 593-85-1 diguanidine carbonate 
• 4949-44-4 ethyl propanoylacetate 
• 50-01-1 guanidine hydrochloride 
• 64-17-5 ethanol 
• 30414-53-0 methyl propanoyl acetate 

Downstream Products

• 15043-03-5 6-ethylpyrimidine-2,4(1H,3H)-dione 
• 5734-67-8 2-amino-4-chloro-6-ethylpyrimidine 
• 1393883-07-2 C₂₁H₁₉FN₆ 
• 1193-85-7 4-ethylpyrimidin-2-amine 
• 514854-13-8 2,4-diamino-6-ethyl-5-iodopyrimidine 
• 514854-15-0 2-amino-6-ethyl-4-methoxypyrimidine 
• 58-14-0 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine 
• 514854-12-7 2,4-diamino-6-ethylpyrimidine 

Relevant academic research and scientific papers

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

Direct synthesis of 5- and 6-substituted 2-aminopyrimidines as potential non-natural nucleobase analogues

A series of 2-aminopyrimidine derivatives, substituted at 5- and 6-positions, were synthesized. The reaction was carried out in a single step by treatment of the corresponding β-ketoester or β-aldehydoester with guanidine hydrochloride in the presence of K2CO3, in a microwave-assisted method without the requirement of solvent. A unique 1:1 co-crystal structure was obtained which shows that a 6-phenyl-2- aminopyrimidinone forms a strong nucleobase-pair with cytosine, involving three hydrogen bonds. The base-pair was found to be as strong as that of natural guanine:cytosine (G:C), signifying the potential application of the synthesized derivatives. Additionally, we also report a second co-crystal involving 5-isopropyl-6-methyl-2-aminopyrimidinone and cytosine in a 1:1 ratio, which also shows strong base-pairing properties. the Partner Organisations 2014.

Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents

NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS

2-Aminopyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.

Pyrimidine Derivatives As HSP90 Inhibitors

The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or